LeonaBio, Inc. (LONA) Stock Score, Valuation & Financial Research

LeonaBio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LONA

LeonaBio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.75. These figures are a research snapshot, not a buy or sell recommendation.

What LeonaBio, Inc. does

LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

LeonaBio is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapeutics for high unmet medical needs, funded primarily through equity financing and strategic licensing agreements.

Products and services

  • The company is developing a pipeline of drug candidates, including lasofoxifene for metastatic breast cancer and ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS).

Customer types

Healthcare providers and patients with high unmet medical needs.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party CROs to conduct clinical trials and manage data collection; specific supplier names are unnamed. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party CMOs for the manufacturing of drug candidates for clinical use; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Sermonix Pharmaceuticals, Inc. — An exclusive global license agreement (excluding Asia and certain Middle Eastern countries) for the development and commercialization of lasofoxifene. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various biopharmaceutical companies developing therapies for breast cancer and neurodegenerative diseases. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting high unmet medical needs Source
  • Strategic licensing of late-stage drug candidates Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical research organizations Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source · Sermonix Pharmaceuticals, Inc.

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LONA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.75
Market capitalization:
22.68M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -141.46M
Free cash flow:
USD -45.73M
Cash:
USD 32.32M
Total debt:
USD 577K
EPS:
USD -32.78

What stands out

  • Free cash flow is USD -45.73M, negative for the stored period.
  • The balance sheet shows USD 32.32M of cash versus USD 577K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 31.75M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LONA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LONA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LONA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LONA to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of LONA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research LONA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.